Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

NCT07753603 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease, TED
Graves Orbitopathy

Interventions

DRUG: linsitinib
DRUG: Placebo

Sponsor

Sling Therapeutics, Inc.